Eptastigmine: A Cholinergic Approach to the Treatment of Alzheimer’s Disease

Cholinesterase inhibitors have a well established role in the symptomatic treatment of patients with Alzheimer’s disease. However, clinical results obtained over the past 20 years have been contradictory. This is perhaps due to the poor systemic tolerability, short duration of action, unknown target Cholinesterase inhibition and tolerance following chronic use of current drugs. These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.